Biology and management of idiopathic myelofibrosis
| Autor: | Moliterno Ar, Smith Bd |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Idiopathic myelofibrosis Myeloproliferative Disorders business.industry Clone (cell biology) Hematopoietic stem cell medicine.disease Prognosis Extramedullary hematopoiesis Lesion medicine.anatomical_structure Oncology Bone Marrow Primary Myelofibrosis Medicine Animals Humans Bone marrow Stem cell medicine.symptom business Bone Marrow Transplantation |
| Zdroj: | Current opinion in oncology. 13(2) |
| ISSN: | 1040-8746 |
| Popis: | Idiopathic myelofibrosis (IMF) is a hematopoietic stem cell disorder characterized by hypercellularity of the bone marrow with an increase in abnormal megakaryocytes, varying degrees of marrow fibrosis, and extramedullary hematopoiesis. The central lesion of the IMF stem cell is not known; however, the marrow fibrosis is a polyclonal reaction to inflammatory mediators generated by the transformed clone. Historical management approaches have centered on improving the patient's blood counts in a palliative manner. Recent reports of autologous and allogeneic bone marrow transplantation (BMT) in IMF patients indicate that stable engraftment occurs easily, the marrow fibrosis is a reversible process, and a graft-versus-fibrosis effect may exist. The goals of future therapies will target marrow fibrosis and harness the graft-versus-fibrosis effect to safely and effectively treat patients with IMF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|